Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Non-Current Assets (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Non-Current Assets for 6 consecutive years, with $71.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 8.69% to $71.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $300.9 million, a 0.94% decrease, with the full-year FY2025 number at $71.6 million, down 8.69% from a year prior.
  • Non-Current Assets was $71.6 million for Q4 2025 at TScan Therapeutics, down from $74.1 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $78.4 million in Q4 2024 to a low of $17.9 million in Q3 2021.
  • A 5-year average of $58.4 million and a median of $73.9 million in 2024 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: surged 233.87% in 2022, then fell 8.69% in 2025.
  • TScan Therapeutics' Non-Current Assets stood at $22.5 million in 2021, then soared by 233.87% to $75.0 million in 2022, then rose by 3.93% to $77.9 million in 2023, then rose by 0.62% to $78.4 million in 2024, then decreased by 8.69% to $71.6 million in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Non-Current Assets are $71.6 million (Q4 2025), $74.1 million (Q3 2025), and $77.4 million (Q2 2025).